We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Amgen Inc | NASDAQ:AMGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 33.02 | 11.86% | 311.41 | 311.40 | 320.00 | 322.54 | 308.68 | 313.42 | 9,644,684 | 05:00:03 |
From Nov 2023 to May 2024
By Ben Glickman
Amgen has received priority review status from the Food and Drug Administration for its biologics license application for a small cell lung cancer treatment.
The Thousand Oaks, Calif.-based pharmaceutical company will get an answer from the FDA on its application in six months, instead of the typical 10 months.
Amgen's BLA is for tarlatamab, a treatment for advanced small cell lung cancer with disease progression on or after platinum-based chemotherapy.
The application is based on the results from a Phase 2 study.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 13, 2023 16:25 ET (21:25 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Amgen Chart |
1 Month Amgen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
